Key Takeaways
- Clinical Bottom Line
- The old stent-versus-surgery framework is no longer enough
- Why EUS-GE has become the option busy endoscopists now need to understand
- What the newer comparative data show
Clinical Bottom Line
| Malignant GOO scenario | 2026 practical answer |
|---|---|
| Life expectancy >2 months, good functional status, surgically fit | Surgical gastrojejunostomy still deserves real consideration. EUS-GE is not an automatic replacement just because it is less invasive. |
| Needs durable palliation but surgery is undesirable or high risk, and expert EUS-GE is available | EUS-guided gastroenterostomy is a strong option because it is more durable than enteral stenting and less invasive than surgery. |
| Very limited prognosis or rapid oral-intake restoration matters most | Enteral stenting can still be reasonable, especially when advanced EUS expertise is unavailable. |
| Multiple luminal obstructions or severely impaired gastric motility | Do not assume an enteral stent will help much. Reassess goals, anatomy, and whether decompressive options fit better. |
| Center without meaningful therapeutic EUS experience | EUS-GE should not be forced into a low-volume setting. Referral or a different palliation strategy is often the safer answer. |
The old stent-versus-surgery framework is no longer enough
Malignant gastric outlet obstruction still demands fast symptom control, but the choice set has changed. For years, the bedside decision was framed as enteral stent for speed or surgical gastrojejunostomy for durability. That is still part of the story, but it is no longer the whole story.
AGA’s expert review remains a useful anchor. If life expectancy is greater than 2 months, functional status is good, and the patient is surgically fit, surgical gastrojejunostomy should still be considered. If the patient is not a candidate for surgical or EUS-guided gastrojejunostomy, enteral stenting remains reasonable. EUS-GE now sits between those options as a minimally invasive bypass with a durability profile closer to surgery than to a trans-tumoral stent.
Why EUS-GE has become the option busy endoscopists now need to understand
ESGE already recommends EUS-guided gastroenterostomy, in an expert setting, for malignant gastric outlet obstruction as an alternative to enteral stenting or surgery. That wording matters. The recommendation is supportive, but it is not casual. The technique belongs in centers that actually do this work.
The reason for the enthusiasm is straightforward. Enteral stents usually restore intake quickly, but tumor ingrowth, overgrowth, or dysfunction drive repeat obstruction. Surgery is more durable, but at the price of invasiveness, recovery burden, and surgical fitness requirements. EUS-GE tries to capture the bypass logic of surgery without the surgical trauma.
What the newer comparative data show
The current comparative literature consistently points in the same direction, even if much of it remains retrospective.
- 2024 propensity-matched comparison: EUS-GE and enteral stenting both achieved 100% technical success, but stent dysfunction was lower after EUS-GE (4.4% vs 20.0%) and hospital stay was shorter.
- 2024 systematic review and meta-analysis: compared with duodenal stenting, EUS-GE was associated with higher clinical success, fewer reinterventions, and fewer adverse events, although procedure time was longer.
- 2026 network meta-analysis: across 54 studies and 6110 patients, both surgery and EUS-GE reduced reintervention compared with enteral stenting, while EUS-GE showed the most favorable overall balance of clinical success, durability, and adverse events.
That does not mean every patient should get EUS-GE. It means the procedure has moved from interesting tertiary-care innovation to a real part of modern malignant GOO planning.
What the data do not justify
Current evidence supports EUS-GE, but it does not erase patient selection.
- It does not erase surgery. A surgically fit patient with a reasonable prognosis can still be well served by surgical gastrojejunostomy.
- It does not erase enteral stenting. When prognosis is short, when rapid palliation is the top priority, or when expert EUS-GE is unavailable, enteral stenting is still a valid choice.
- It does not erase center effect. Most favorable EUS-GE data come from experienced units. That matters when translating results into general practice.
A practical modality table for daily decision-making
| Modality | Best fit | Main limitation |
|---|---|---|
| Enteral stent | Need for quick palliation, short prognosis, or no access to EUS-GE expertise | Higher symptom recurrence and reintervention |
| EUS-guided gastroenterostomy | Need for durable palliation without surgery, favorable anatomy, expert therapeutic EUS support | Not a casual procedure, and not every center should offer it |
| Surgical gastrojejunostomy | Good functional status, longer expected survival, surgically fit patient, or anatomy unfavorable for endoscopic bypass | Greater invasiveness and longer recovery |
Where I would be cautious in 2026
- Do not call EUS-GE the default for every malignant GOO referral.
- Do not ignore the patient’s prognosis and performance status just because the endoscopic option feels elegant.
- Do not send a frail patient through repeated procedures when goals-of-care discussions point toward simpler palliation.
- Do not let the availability of LAMS distort the question. The right endpoint is durable symptom relief with the least overall burden for that patient.
Selected references
- AGA Clinical Practice Update on the Optimal Management of the Malignant Alimentary Tract Obstruction. Clin Gastroenterol Hepatol. 2021.
- ASGE Guideline on the Role of Endoscopy in the Management of Benign and Malignant Gastroduodenal Obstruction. Gastrointest Endosc. 2021.
- ESGE Guideline on Therapeutic Endoscopic Ultrasound. 2022.
- Endoscopic Ultrasound-Guided Gastroenterostomy versus Enteral Stenting for Malignant Gastric Outlet Obstruction: A Retrospective Propensity Score-Matched Study. Cancers (Basel). 2024.
- Endoscopic ultrasound-guided gastroenterostomy versus duodenal stenting for gastric outlet obstruction: A systematic review and meta-analysis. Medicine (Baltimore). 2024.
- A network meta-analysis on the optimal treatment of malignant gastric outlet obstruction. Ther Adv Gastroenterol. 2026.
Last reviewed April 17, 2026. This update is written for clinicians choosing among enteral stenting, EUS-guided gastroenterostomy, and surgical bypass in real-world malignant gastric outlet obstruction.
